证券代码：688076 证券简称：诺泰生物 公告编号：2025-041 江苏诺泰澳赛诺生物制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 26 日(星期一)下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （一）会议召开时间：2025 年 5 月 26 日下午 13:00-14:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于 2025 年 5 月 19 日(星期一)至 5 月 25 日(星期日)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinopep.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 江 ...

Group 1 - The "2025 China Listed Companies Brand Value List" was released, showcasing the brand value of listed companies in China, with a total brand value of 20.46 trillion yuan, an increase of 2.65 trillion yuan or 14.9% year-on-year [4][5] - Tencent and Alibaba ranked first and second in brand value, with values of 26,824 billion yuan and 18,335 billion yuan respectively, followed by China Mobile, Pinduoduo, and Kweichow Moutai in the top five [4] - The event also introduced the "Yangtze River Delta Listed Companies Brand Value List TOP100," highlighting the brand value and market influence of companies in that region [1][2] Group 2 - The event featured discussions on the integration of brand and cutting-edge digital technology, emphasizing the trend of brand IP (intellectual property) development [5] - A total of 30 companies were recognized as classic brand cases, including Agricultural Bank of China, Yili Group, and GAC Group, while 10 executives were awarded as Chief Brand Officers [5] - The "Daily Economic News" announced its AI strategy, aiming to create a new type of intelligent media group and enhance brand communication through innovative products [6][7]

Group 1: Industry Overview - The overall revenue growth rate for the pharmaceutical and biotechnology sector in Q1 2025 was -4.8%, with a net profit growth rate of -12.2%[3] - The raw material drug sector showed resilience with a revenue growth rate of -3.6% and a net profit growth rate of 10.5% in Q1 2025, benefiting from demand recovery and price stabilization[3] Group 2: Profitability and Financial Performance - In 2024, major raw material drug companies saw an increase in gross margin and net margin by 0.78 percentage points and 0.39 percentage points respectively, while Q1 2025 saw a decline in average gross margin and net margin by 0.64 percentage points and 1.87 percentage points respectively[5] - The average operating cash flow for major raw material drug companies reached 10.04 billion yuan in 2024, a 14.65% increase from 2023, indicating a positive trend[31] Group 3: Capital Expenditure Trends - Capital expenditure for major raw material drug companies in 2024 totaled 7.242 billion yuan, reflecting a year-over-year decrease of 4.12%[36] - The capital expenditure to depreciation ratio for the raw material drug sector decreased from 1.79 in 2023 to 1.27 in 2024, indicating ongoing capacity reduction and structural adjustments[36] Group 4: Investment Strategy - Investment recommendations focus on selecting raw material drug companies with strong growth attributes and stable competitive landscapes, particularly in bulk and specialty raw materials[44] - Companies like Guobang Pharmaceutical and Tianyu Co., Ltd. are highlighted for their favorable supply dynamics and demand recovery[44] Group 5: Risk Factors - Risks include intensified competition leading to suboptimal recovery in product prices and volumes, production safety incidents, and exchange rate fluctuations impacting profitability[47]

Core Insights - The "2025 China Listed Companies Brand Value List" was released at a conference themed "Digital Intelligence Upgrading, Brand Resonance" in Shanghai, marking the ninth edition of this event [1][3] - The total brand value of the top 100 companies on the list reached 20.46 trillion yuan, an increase of 2.65 trillion yuan or 14.9% year-on-year [7] - Tencent and Alibaba retained the top two positions with brand values of 26,824 billion yuan and 18,335 billion yuan, respectively [7] Brand Value Rankings - The event introduced a new "Yangtze River Delta Listed Companies Brand Value List TOP100," showcasing the brand value and market influence of companies in this economically significant region [1][12] - The Yangtze River Delta region's listed companies collectively have a brand value of 64,965 billion yuan, with eight companies exceeding 1,000 billion yuan in brand value [12] Brand Development Trends - Media communication is emphasized as a key accelerator for brand building, with companies encouraged to collaborate for mutual growth [2] - The integration of digital technologies and traditional brand promotion is reshaping brand strategies, leading to a trend towards brand IP (intellectual property) development [14][19] Investment Opportunities - The "Everyday Brand 100 Index," launched in May 2022, has shown strong performance, with significant excess returns compared to major indices [13] - The index's sample companies have an average market capitalization of 353.7 billion yuan, indicating a strong large-cap focus [13] Strategic Insights - The conference highlighted the importance of aligning brand values with local culture and consumer engagement for international brands operating in China [16] - The rise of AI in marketing is seen as a transformative opportunity for Chinese brands to expand globally, with companies like BlueFocus leveraging AI to enhance operational efficiency [19][20] Media and Technology Integration - The "Everyday Economic News" is adopting an AI-driven strategy to redefine media boundaries and enhance brand communication [20][23] - The establishment of a national first "Media Intelligence Incubator Platform" aims to create practical media solutions through human-machine collaboration [23]

[Table_Reportdate] 2025年05月09日 [诺泰生物（ Table_NewTitle] 688076）：业绩保持高增长， 多肽领先地位持续巩固 ——公司简评报告 [table_main] 投资要点 22% [Table_QuotePic] -30% -20% -9% 1% 12% 33% 43% 24-05 24-08 24-11 25-02 诺泰生物 沪深300 [相关研究 Table_Report] 《诺泰生物（688076）：多肽优势持 续扩大，业绩显著超预期——公司简 评报告》 2024.08.27 《诺泰生物（688076）：业绩强劲增 长，产销研齐头并进——公司简评报 告》 2024.04.02 《诺泰生物（688076）：业绩超预期， 自主产品为主要增长引擎——公司 简评报告》 2023.10.23 公 司 简 评 医 药 生 物 [Table_invest] 买入（维持） 报告原因：业绩点评 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 公 司 研 究 [证券分析师 Table_Authors] 杜永宏 S06305 ...

证券研究报告 | 2025年05月06日 诺泰生物（688076.SH） 优于大市 业绩表现亮眼，多肽产能布局领先 业绩表现亮眼，利润端增速快于收入端。2024 年公司实现营收 16.25 亿元 （+57.21%），归母净利润 4.04 亿元（+148.19%），扣非归母净利润 4.08 亿元（+142.60%）。其中 24Q4 单季营收 3.73 亿元（+14.96%），归母 净利润 0.54 亿元（-23.98%），扣非归母净利润 0.53 亿元（-33.37%）， 2024 年业绩亮眼，公司 BD 团队持续突破，客户规模不断扩大，规模效 应体现，利润端增速快于收入端。2025 年一季度营收 5.66 亿元 （+58.96%），归母净利润 1.53 亿元（+130.10%），扣非归母净利润 1.52 亿元（+131.79%），延续了良好的增长趋势。 自主选择产品与定制类业务均实现快速增长。分业务来看，2024 年自主选 择产品实现收入 11.3 亿元，同比增长 80%，其中原料药及中间体营收 9.4 亿（+127%），主要得益于司美格鲁肽、利拉鲁肽等品种的放量，制 剂营收 1.8 亿，同比下滑 13%，主 ...

Core Viewpoint - The company reported significant revenue and profit growth for 2024 and Q1 2025, indicating strong operational performance and market demand for its products [1][2]. Financial Performance - In 2024, the company achieved revenue of 1.625 billion yuan, a year-on-year increase of 57.21%, and a net profit attributable to shareholders of 404 million yuan, up 148.19% [1]. - For Q1 2025, the company reported revenue of 566 million yuan, a growth of 58.96%, and a net profit of 153 million yuan, reflecting a 130.10% increase [1][2]. - The gross margin for 2024 was 67.68%, an increase of 6.71 percentage points, while the net profit margin was 24.61%, up 8.60 percentage points [2]. Product and Market Development - The company's self-selected products, including peptides, oligonucleotides, and formulations, showed robust growth, with revenue from self-selected products reaching 1.129 billion yuan, a 79.49% increase [4]. - Strategic collaborations have been established for various innovative drug raw materials and formulations, enhancing market presence and growth potential [4]. - The company is expanding its production capacity, with new facilities expected to contribute significantly to output in the coming years [4]. CDMO Business - The CDMO segment generated revenue of 494 million yuan in 2024, a 22.34% increase, with large orders being progressively delivered [5]. - Long-term contracts with major pharmaceutical companies, including a $100 million contract with a European firm, have commenced delivery, indicating strong demand for CDMO services [5]. Future Projections - Revenue forecasts for 2025-2027 are projected at 2.276 billion yuan, 3.218 billion yuan, and 4.576 billion yuan, with growth rates of 40.06%, 41.42%, and 42.19% respectively [5]. - Net profit estimates for the same period are 559 million yuan, 755 million yuan, and 1.027 billion yuan, with growth rates of 38.20%, 35.09%, and 36.02% respectively [5].

据悉，诺泰生物旗下的多肽原料药产品，涵盖了司美格鲁肽原料药。司美格鲁肽的原研厂家是诺和诺 德。诺泰生物表示，多肽行业需求非常大，优质产能一定稀缺，针对头部的全球优质客户，需要公司具 有前瞻性地布局相应产能；公司已与全球多家客户签订相关战略合作协议，除了传统的欧美市场外，同 时也开拓了拉美、中东等新兴市场。 平台：部分进口慢病用药"供需两旺" 美团数据显示，截至目前，平台部分进口慢病用药，如治疗乳腺癌的辉瑞阿诺新搜索量日环比增长翻 倍；晖致旗下治疗高血脂、高血压的立普妥、络活喜，搜索量突破年度月均峰值。 美团自营大药房相关负责人就此表示，（美团自营大药房）进口原研药供给稳定充足，暂未发现上游供 给受到影响，大家按需购药即可。据悉，作为美团医药健康旗下的自营快递电商，美团自营大药房已覆 盖市面上常见的进口原研药，产品共计1224个。为响应部分用户对进口药的需求，美团自营大药房已经 启动多项举措，确保供给稳定、价格稳定，保障高需求进口药平价供应。 （文章来源：广州日报） 作为GLP-1等多肽原料药供应商的诺泰生物，在过去几年收获了减肥药市场部分红利，收入持续增长。 公司2024年六成以上的收入来源于海外。就在近日， ...

Core Viewpoint - The stock of Nuotai Bio (688076) shows a strong performance with a comprehensive score of 51.47, indicating a robust market position and potential for future growth [1][3]. Stock Performance - The current stock price is 52.95 CNY, with a 5-day average cost of 53.64 CNY and a 20-day average cost of 51.35 CNY [1]. - The stock has not experienced any limit-up or limit-down events in the past year [1]. Northbound Capital Data - Northbound capital holds 3.1526 million shares, accounting for 1.43% of the circulating shares [1]. - There was a net purchase of 336,300 shares yesterday, with a daily increase ratio of 0.154% [1]. - The 5-day and 20-day increase ratios are 0.125% and 0.166%, respectively [1]. Technical Analysis - The short-term resistance level is at 54.59 CNY, while the short-term support level is at 53.01 CNY [2]. - The stock price has broken below the short-term support level, suggesting a cautious approach in the short term [2]. - The K-line patterns indicate a potential bottom reversal and heavy pressure at the upper levels, suggesting a possible recovery [2]. Financial Data - The latest financial report shows earnings per share of 0.69 CNY and an operating profit of 178 million CNY [2]. - The sales gross margin stands at 70.204% [2]. - The net profit reported is approximately 147.87 million CNY [3]. Industry and Concept Sectors - The stock is associated with several sectors, including medical services (0.92%), CRO (-0.05%), influenza (0.40%), and hepatitis concepts (0.20%) [2].

China Chengxin International Credit Rating Co.,Ltd. [2025]152 中诚信国际关于终止江苏诺泰澳赛诺生物制药股份有限公司 主体和相关债项信用评级的公告 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物"或"公司"） 发行的"诺泰转债"由中诚信国际信用评级有限责任公司（以下简称"中诚信国 际"）进行相关评级工作。2024 年 5 月 27 日，中诚信国际对公司及上述债券进 行定期跟踪评级，维持诺泰生物主体信用等级为 A + k，评级展望为稳定，维持"诺 泰转债"债项信用等级为 A + k。 近日，公司发布公告称，根据《江苏诺泰澳赛诺生物制药股份有限公司向不 特定对象发行可转换公司债券募集说明书》的约定，已触发"诺泰转债"的有条 件赎回条款，且经公司董事会审议，公司决定行使"诺泰转债"的提前赎回权， 对赎回登记日（即 2025 年 4 月 24 日）登记在册的"诺泰转债"全部赎回。截至 2025 年 4 月 24 日（赎回登记日收市后），累计共有 429,956,000 元"诺泰转债" 已转换为公司股本，累计转股数为 10,168,365 股，占"诺泰 ...